Henry Schein, Inc. is a global distributor of healthcare products and services, primarily serving dental and medical practitioners with a comprehensive suite of merchandise, equipment, pharmaceuticals, and practice management software. Operating within the Healthcare sector, specifically in Medical Distribution, the company has established itself as a value-added partner since its founding in 1932. The company's business model focuses on providing a broad product portfolio and essential services to a diverse customer base, including private practices, laboratories, and institutional healthcare providers. In its most recent reported quarters, Henry Schein demonstrated a mixed performance. For Q3 2025, the company reported an actual EPS of $1.38 against an estimate of $1.27912, and revenue of $3.339 billion. This followed a Q2 2025 where actual EPS was $1.10, missing the estimate of $1.19055, with revenue at $3.240 billion. Prior to this, Q1 2025 saw actual EPS of $1.15, beating the estimate of $1.11013, and Q4 2024 reported actual EPS of $1.19 against an estimate of $1.20888. Revenue trends show a general increase over these periods, with Q4 2025 revenue reaching $3.437 billion, exceeding estimates. Looking at the historical streak analysis, Henry Schein has shown an upward trajectory in revenue, with Q4 2025 revenue significantly beating estimates. While EPS performance has been more variable, with beats in Q1 2025 and Q3 2025, and misses in Q2 2025 and Q4 2024, the overall revenue growth suggests underlying business strength. Recent news indicates a significant board overhaul at Henry Schein, including a reduction in board size and the retirement of Chairman Stanley M. Bergman, aimed at streamlining operations and enhancing decision-making agility. This governance restructuring is occurring alongside recognition from value fund manager Ari Sass of the M.D. Sass Concentrated Value ETF, who identified Henry Schein as a bargain growth stock. Investors will be watching for how these governance changes impact strategic execution and whether the positive sentiment from value investors translates into sustained interest and improved operational performance in upcoming quarters. Key will be observing the company's ability to translate revenue growth into consistent EPS beats and manage its operational direction under the new governance structure.
